Literature DB >> 17238985

MR-guided intervention in women at high hereditary risk of breast cancer due to both family and personal history of breast cancer.

Petra Viehweg1, Thorsten Bernerth, Anke Heinig, Marion Kiechle, Jörg Buchmann, Heinz Koelbl, Michael Laniado, Sylvia Helen Heywang-Köbrunner.   

Abstract

The purpose of this study was to assess the value of magnetic resonance imaging (MRI)-guided intervention in women with a significant hereditary susceptibility to breast cancer due to both family and personal history of breast cancer (heterozygote risk >20%). Thirty women were referred for MR-guided intervention. MR examinations (1.0 T, T1-weighted 3D FLASH, 0.15 mmol Gd-DTPA/kg body weight, prone position) were performed using a system which allows vacuum-assisted breast biopsy or wire localization. Histologic findings in 41 procedures revealed six invasive carcinomas, eight ductal carcinomas in situ and two atypical ductal hyperplasias. Twenty-three benign histologic results were verified by an MR-guided intervention, retrospective correlation of imaging and histology and by subsequent follow-up. In two lesions the indication dropped as the enhancing lesion was no longer visible on the date of planned intervention. Absent enhancement was confirmed by short-term re-imaging of the non-compressed breast and by follow-up.

Entities:  

Mesh:

Year:  2006        PMID: 17238985     DOI: 10.1111/j.1524-4741.2006.00344.x

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  2 in total

1.  Imaging studies for the early detection of breast cancer.

Authors:  Sylvia H Heywang-Köbrunner; Ingrid Schreer; Walter Heindel; Alexander Katalinic
Journal:  Dtsch Arztebl Int       Date:  2008-08-04       Impact factor: 5.594

2.  The use of magnetic resonance mammography in women at increased risk for developing breast cancer.

Authors:  Tadeusz J Popiela; Wojciech Kibil; Izabela Herman-Sucharska; Andrzej Urbanik
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2012-10-30       Impact factor: 1.195

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.